Abstract
The catalytic activity of the histone deacetylase (HDAC) enzymes is directly relevant to the pathogenesis of cancer as well as several other diseases. HDAC inhibitors have been shown to have the potential to treat several types of cancers. The role of computational study of the HDAC enzymes is reviewed, with particular emphasis on the important role of molecular modeling to the development of HDAC inhibitors with improved efficacy and selectivity. The use of two computational approaches — one structure-based, and the second ligand-based — toward inhibitors against the different HDAC sub-classes, are summarized.
Current Topics in Medicinal Chemistry
Title: Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors
Volume: 9 Issue: 3
Author(s): Difei Wang
Affiliation:
Abstract: The catalytic activity of the histone deacetylase (HDAC) enzymes is directly relevant to the pathogenesis of cancer as well as several other diseases. HDAC inhibitors have been shown to have the potential to treat several types of cancers. The role of computational study of the HDAC enzymes is reviewed, with particular emphasis on the important role of molecular modeling to the development of HDAC inhibitors with improved efficacy and selectivity. The use of two computational approaches — one structure-based, and the second ligand-based — toward inhibitors against the different HDAC sub-classes, are summarized.
Export Options
About this article
Cite this article as:
Wang Difei, Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors, Current Topics in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/156802609788085287
DOI https://dx.doi.org/10.2174/156802609788085287 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Role of Metallothionein in Inflammatory Lung Diseases
Current Respiratory Medicine Reviews Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Challenges from Clustering Analysis to Knowledge Discovery in Molecular Biomechanics
Current Bioinformatics Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer
Current Cancer Drug Targets PARP Inhibitors in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets The Role of Autophagy in Rheumatic Disease
Current Drug Targets Current Treatment Concepts of CML
Current Cancer Drug Targets CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer
Current Cancer Drug Targets Ethanol Extract of Achillea fragrantissima Enhances Angiogenesis through Stimulation of VEGF Production
Endocrine, Metabolic & Immune Disorders - Drug Targets The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Current Molecular Medicine Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Novel Applications of the Paired-End diTag (PET) Technology in Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets